Skip to main content
Signal8
Launch Terminal

Valion Bio, Inc. (VBIO)

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Valion Bio, Inc. logo

Valion Bio, Inc.

NASDAQ:VBIOHealthcare
-10.83%$0.5500
AH$0.5304-3.56%vs close
Mkt Cap$1.19M
Float2.15M
O/S2.16M
Vol
$ Vol
RVOL
Inst Own0.7%
SI5.4%
Earnings
Dilution
Valion Bio, Inc. logoNASDAQ:VBIO$0.5500-10.83%
FormDescription
8-K
8.01,9.01
2
8-K
1.01,3.02,9.01
5
8-K
8.01,9.01
4
8-K
8.01,9.01
4
424B3
Prospectus
6
EFFECT
Notice of Effectiveness
1
EFFECT
Notice of Effectiveness
1
S-3
REGISTRATION STATEMENT
7
DEF 14A
DEFINITIVE PROXY STATEMENT
5
8-K
CURRENT REPORT
2
8-K
CURRENT REPORT
3
8-K
CURRENT REPORT
4
S-3
REGISTRATION STATEMENT
5
8-K
8.01,9.01
2
DRS
SEC Filing
7
PRE 14A
PRELIMINARY PROXY STATEMENT
6
8-K
CURRENT REPORT
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.02,7.01,9.01
4
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13D/A
Beneficial Ownership Report (Active, Amended)
13D/A
Beneficial Ownership Report (Active, Amended)

1-25 of 401

…

Recent SEC filings with analysis